Aug 7, 2019 · TAK-639 is a topical, nine-amino acid, synthetic, C-type natriuretic peptide analog in Phase 1 development for the treatment of ocular hypertension (OHT) and primary open-angle …

SHP-639: a CNP modulators Drug, Initially developed by Shire Pharmaceuticals Services Ltd., Now, its global highest R&D status is Pending, Mechanism: CNP modulators(2',3'-cyclic …

Nov 21, 2022 · TAK-639 is postulated to lower intraocular pressure (IOP) through a novel mechanism of action (MOA) that increases trabecular meshwork outflow. We investigated the …

By continuing, I agree to the and authorize you to charge my payment method at the prices, frequency and dates listed on this page until my order is fulfilled or I cancel, if permitted. Tone …

Safety and tolerability of three different concentrations (0.1%, 03%, 0.6%) of the investigational SHP639 eye drops will be evaluated in participants with high eye pressure or primary open …

Mar 1, 2020 · TAK-639 is postulated to lower intraocular pressure (IOP) through a novel mechanism of action (MOA) that increases trabecular meshwork outflow. We investigated the …

Shire initiates phase I study of SHP-639 in intraocular hypertension and primary open-angle glaucoma

TAK 639 (also designated as SHP 639), a 9-amino acid, synthetic, C-type natriuretic peptide analog, is being developed by Takeda (previously Shire) for the

TAK-639 is a topical, 9-amino acid, synthetic, C-type natriuretic peptide analog in development for the treatment of primary open-angle glaucoma and ocular hypertension.

SHP-639是由Shire Pharmaceuticals研发的一种合成多肽，是一种NPR3激动剂。 目前该药物最高研发阶段为无进展，用于治疗高眼压和开角型青光眼。